CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderson, H.
Right arrow Articles by Roberge, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, H.
Right arrow Articles by Roberge, M.

Cell Growth & Differentiation, Vol 7, Issue 1 83-90, Copyright © 1996 by American Association of Cancer Research


ARTICLES

Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells

H Anderson and M Roberge
Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, Canada.

DNA topoisomerase II (topo II) is required at mitosis in yeast for high chromosome condensation and for chromosome segregation. Recent studies on intact mammalian cells using topo II inhibitors that do not stabilize cleavable complexes also suggest a requirement for topo II for complete chromosome condensation and perhaps also for entry into mitosis. We have investigated the effects of merbarone, ICRF-187, and aclarubicin, three topo II inhibitors that do not stabilize the cleavable complex, on entry into mitosis and on chromosome condensation in BHK and in tsBN2 cells. We have compared their effects with those of etoposide, a topo II inhibitor that stabilizes the cleavable complex. All inhibitors induced a concentration-dependent G2 delay or arrest that could be overcome with fostriecin or okadaic acid or by inactivation of RCC1 in tsBN2 cells. Mitotic chromosomes from cells treated with etoposide were extensively fragmented, whereas mitotic chromosomes from cells treated with merbarone, ICRF-187, or aclarubicin were intact but elongated and tangled. These results provide strong evidence that topo II activity is required in chromosome condensation for final coiling of the chromatids. Our results also indicate that protein phosphatases and RCC1 play a role in G2 delay induced by all inhibitors, whether they do or do not stabilize the cleavable complex.


This article has been cited by other articles:


Home page
BloodHome page
U. Schroeder, K. M. Bernt, B. Lange, J. Wenkel, J. Jikai, D. Shabat, R. Amir, N. Huebener, A. G. Niethammer, C. Hagemeier, et al.
Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia
Blood, July 1, 2003; 102(1): 246 - 253.
[Abstract] [Full Text] [PDF]


Home page
Cell Growth Differ.Home page
A. P. Null, J. Hudson, and G. J. Gorbsky
Both {alpha} and {beta} Isoforms of Mammalian DNA Topoisomerase II Associate with Chromosomes in Mitosis
Cell Growth Differ., July 1, 2002; 13(7): 325 - 333.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. B. Deming, C. A. Cistulli, H. Zhao, P. R. Graves, H. Piwnica-Worms, R. S. Paules, C. S. Downes, and W. K. Kaufmann
The human decatenation checkpoint
PNAS, October 9, 2001; 98(21): 12044 - 12049.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
Y. Kwon, B. S. Shin, and I. K. Chung
The p53 Tumor Suppressor Stimulates the Catalytic Activity of Human Topoisomerase II{alpha} by Enhancing the Rate of ATP Hydrolysis
J. Biol. Chem., June 16, 2000; 275(24): 18503 - 18510.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
D. M. Sauve, H. J. Anderson, J. M. Ray, W. M. James, and M. Roberge
Phosphorylation-induced Rearrangement of the Histone H3 NH2-terminal Domain during Mitotic Chromosome Condensation
J. Cell Biol., April 19, 1999; 145(2): 225 - 235.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
P. Grue, A. Grässer, M. Sehested, P. B. Jensen, A. Uhse, T. Straub, W. Ness, and F. Boege
Essential Mitotic Functions of DNA Topoisomerase II{alpha} Are Not Adopted by Topoisomerase II{beta} in Human H69 Cells
J. Biol. Chem., December 11, 1998; 273(50): 33660 - 33666.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
P. Munoz, M. Z. Zdzienicka, J.-M. Blanchard, and J. Piette
Hypersensitivity of Ku-Deficient Cells toward the DNA Topoisomerase II Inhibitor ICRF-193 Suggests a Novel Role for Ku Antigen during the G2 and M Phases of the Cell Cycle
Mol. Cell. Biol., October 1, 1998; 18(10): 5797 - 5808.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
J. M. Fortune and N. Osheroff
Merbarone Inhibits the Catalytic Activity of Human Topoisomerase II{alpha} by Blocking DNA Cleavage
J. Biol. Chem., July 10, 1998; 273(28): 17643 - 17650.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
Y. Kwon, B. S. Shin, and I. K. Chung
The p53 Tumor Suppressor Stimulates the Catalytic Activity of Human Topoisomerase II{alpha} by Enhancing the Rate of ATP Hydrolysis
J. Biol. Chem., June 16, 2000; 275(24): 18503 - 18510.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. B. Deming, C. A. Cistulli, H. Zhao, P. R. Graves, H. Piwnica-Worms, R. S. Paules, C. S. Downes, and W. K. Kaufmann
The human decatenation checkpoint
PNAS, October 9, 2001; 98(21): 12044 - 12049.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1996 by the American Association of Cancer Research.